Alnylam Pharmaceuticals IncFind Ratings Reports
ALNYLAM PHARMACEUTICALS INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ALNYLAM PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 8.91 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 23.20% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY16||Q3 FY15|
|Net Sales ($mil)||13.65||6.32|
|Net Income ($mil)||-104.07||-76.79|
|Balance Sheet||Q3 FY16||Q3 FY15|
|Cash & Equiv. ($mil)||713.14||1016.21|
|Total Assets ($mil)||1312.91||1436.14|
|Total Debt ($mil)||150.0||0.0|
|Profitability||Q3 FY16||Q3 FY15|
|Gross Profit Margin||-755.81||-1155.28|
|Return on Assets||-29.54||-15.37|
|Return on Equity||-38.21||-16.7|
|Debt||Q3 FY16||Q3 FY15|
|Share Data||Q3 FY16||Q3 FY15|
|Shares outstanding (mil)||85.77||84.71|
|Div / share||0.0||0.0|
|Book value / share||11.83||15.6|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1444336.0||1097178.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 3.54 indicates a premium versus the S&P 500 average of 2.84 and a significant discount versus the industry average of 11.43. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ALNYLAM PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.
|ALNY NM||Peers 34.33||ALNY NM||Peers 27.22|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ALNY's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ALNY's P/CF is negative making the measure meaningless.
|ALNY NM||Peers 24.82||ALNY NA||Peers 0.41|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ALNY's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ALNY 3.54||Peers 11.43||ALNY -70.67||Peers 3.61|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ALNY is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ALNY is expected to significantly trail its peers on the basis of its earnings growth rate.
|ALNY 96.31||Peers 136.62||ALNY -35.29||Peers 532.92|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ALNY is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ALNY significantly trails its peers on the basis of sales growth